Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

.

Two previous studies with EVP-6124 in Alzheimer's disease patients demonstrated that it was well tolerated and produced significant effects on a variety of cognitive measures of brain function such as attention, memory and executive function (complex thinking tasks). EVP-6124 had procognitive effects in two separate clinical trials: one study conducted in Alzheimer's disease patients already treated with Acetyl Choline Esterase Inhibitors (AChEI) and one in Alzheimer's disease patients not on AChEI therapy (naive patients).

EVP-6124 is a selective agonist for the alpha-7 subtype of the nicotinic acetylcholine receptor and is being developed by EnVivo for potential cognitive enhancement in both schizophrenia and Alzheimer's patients. It has been shown to have excellent CNS penetration, oral bioavailability, pharmacokinetics and metabolic profile.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, cognitive disorders and schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which has completed Phase I studies, and seve
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that it ... Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is an ... and how agriculture impacts their daily lives. This unique exhibit also features a birthing ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry ... market with a focus on the Chinese situation. Major companies included in the propanol ... Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), a ... and marketing biopharmaceutical,products, today announced its unaudited financial ... Second Quarter 2008 Financial Highlights: ... second quarter 2007 to ...
... To protect potential patients from,being unwitting victims in ... Stem Cell Institute LLC (RSCI),( http://www.RepairStemCells.org ) and ... of the industry,s first standards of,excellence for Repair ... RSC, also known as Adult Stem Cells. Among ...
... on Monday, August 18, 2008, ... Beginning at 1:00 PM Eastern Time, LIVINGSTON, N.J., Aug. ... in,advanced injection technologies, today announced that it plans to report,its results ... the morning,of Thursday, August 14, 2008., Milestone Scientific will also ...
Cached Biology Technology:3SBio Inc. Announces Second Quarter 2008 Results 23SBio Inc. Announces Second Quarter 2008 Results 33SBio Inc. Announces Second Quarter 2008 Results 43SBio Inc. Announces Second Quarter 2008 Results 53SBio Inc. Announces Second Quarter 2008 Results 63SBio Inc. Announces Second Quarter 2008 Results 73SBio Inc. Announces Second Quarter 2008 Results 83SBio Inc. Announces Second Quarter 2008 Results 93SBio Inc. Announces Second Quarter 2008 Results 103SBio Inc. Announces Second Quarter 2008 Results 113SBio Inc. Announces Second Quarter 2008 Results 123SBio Inc. Announces Second Quarter 2008 Results 133SBio Inc. Announces Second Quarter 2008 Results 143SBio Inc. Announces Second Quarter 2008 Results 15Repair Stem Cell Institute Announces Industry's First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics 2Milestone to Report Results for 2008 Second Quarter on Thursday, August 14, 2008 2
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Jan. 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical ... cells and tissues including muscle, bone, fat, red blood ... awarded a $1.5 million grant from the Muscular Dystrophy ... Muscular Dystrophy (DMD), a disabling neuromuscular disease in which ...
... that nations should abandon the concept of carbon emissions ... might lead to genuine reductions in the amount of ... provide a mechanism for reducing climate change. Details of ... Interdisciplinary Environmental Review . Carbon emissions trading ...
... The number of women who die from complications of ... last two decades thanks to improved monitoring and better ... report,s lead researcher, Joy Hawkins, MD, professor of anesthesiology ... Colorado School of Medicine, said the risks have been ...
Cached Biology News:Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031 2Carbon swap bank to beat climate change 2Carbon swap bank to beat climate change 3Deaths from anesthesia during childbirth plummet 2
... Measurement of light production by luciferase-cDNA ... a valuable technique in the development of ... is used as an indicator for the ... the luciferase enzyme is due to advantages ...
... detection of apoptosis and mitochondrial membrane potential. ... early indication of the initiation of cellular ... a collapse in the electrochemical gradient across ... change in the membrane potential (YD). Loss ...
... kit measures mitochondria intactness and detects ... potential. Features and Benefits: ... staining isolated mitochondria and for assaying ... the reagents required for the detection ...
... is expressed in g per ml and is ... pH 6.8, of a 1 mg per ml ... concentration to agglutinate a 2% suspension of human ... at 25 C. Preparation Note: Affinity ...
Biology Products: